Analysts expect bluebird bio Inc (NASDAQ:BLUE) to post sales of $10.36 million for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for bluebird bio’s earnings. The lowest sales estimate is $5.00 million and the highest is $12.20 million. bluebird bio posted sales of $4.17 million in the same quarter last year, which suggests a positive year-over-year growth rate of 148.4%. The firm is expected to issue its next quarterly earnings results on Wednesday, February 20th.
According to Zacks, analysts expect that bluebird bio will report full year sales of $44.59 million for the current year, with estimates ranging from $37.00 million to $47.54 million. For the next financial year, analysts expect that the company will post sales of $73.26 million, with estimates ranging from $55.67 million to $121.59 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow bluebird bio.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The firm had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same period last year, the firm posted ($1.73) EPS. bluebird bio’s quarterly revenue was up 49.2% on a year-over-year basis.
BLUE has been the topic of a number of analyst reports. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research report on Friday, July 13th. Maxim Group lowered their price objective on shares of bluebird bio to $163.00 and set a “hold” rating on the stock in a research report on Monday, July 30th. Piper Jaffray Companies reiterated a “buy” rating on shares of bluebird bio in a research report on Thursday, August 2nd. BMO Capital Markets reiterated a “buy” rating and issued a $208.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Finally, SunTrust Banks reiterated a “buy” rating and issued a $223.00 price objective on shares of bluebird bio in a research report on Friday, August 3rd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and sixteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $209.74.
NASDAQ:BLUE opened at $126.33 on Friday. bluebird bio has a 1-year low of $102.21 and a 1-year high of $236.17. The firm has a market capitalization of $7.38 billion, a P/E ratio of -16.39 and a beta of 2.31.
In other bluebird bio news, insider Philip D. Gregory sold 1,800 shares of the firm’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $137.38, for a total value of $247,284.00. Following the completion of the sale, the insider now owns 31,971 shares of the company’s stock, valued at $4,392,175.98. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey T. Walsh sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $175.40, for a total value of $3,508,000.00. Following the completion of the sale, the insider now directly owns 44,238 shares of the company’s stock, valued at approximately $7,759,345.20. The disclosure for this sale can be found here. In the last three months, insiders sold 44,859 shares of company stock valued at $7,159,367. 3.00% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in bluebird bio by 8.1% in the third quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock valued at $1,186,058,000 after acquiring an additional 605,797 shares during the period. BlackRock Inc. raised its stake in shares of bluebird bio by 7.9% during the 3rd quarter. BlackRock Inc. now owns 2,952,089 shares of the biotechnology company’s stock worth $431,005,000 after buying an additional 216,914 shares during the last quarter. OppenheimerFunds Inc. raised its stake in shares of bluebird bio by 3.0% during the 2nd quarter. OppenheimerFunds Inc. now owns 794,126 shares of the biotechnology company’s stock worth $124,638,000 after buying an additional 23,016 shares during the last quarter. First Trust Advisors LP raised its stake in shares of bluebird bio by 63.2% during the 3rd quarter. First Trust Advisors LP now owns 601,883 shares of the biotechnology company’s stock worth $87,875,000 after buying an additional 233,175 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of bluebird bio by 86.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 581,695 shares of the biotechnology company’s stock worth $84,926,000 after buying an additional 269,074 shares during the last quarter. 98.63% of the stock is owned by institutional investors.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Further Reading: What are the Different Types of Leveraged Buyouts?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.